SLC15A4 controls endolysosomal TLR7-9 responses by recruiting the innate immune adaptor TASL
Phase 2 Side-Effect Frequencies at 4.5 mg/week (Lancet 2021) Side Effect Nausea Incidence at 4.5 mg/week 47% Side Effect Injection-site reactions Incidence at 4.5 mg/week 43% Side Effect Constipation Incidence at 4.5 mg/week 21% Side Effect Fatigue Incidence at 4.5 mg/week 20% Side Effect Allergic reactions (any) Incidence at 4.5 mg/week 10% Side Effect Vomiting Incidence at 4.5 mg/week 8% Side Effect Loose stools Incidence at 4.5 mg/week 7% Side Effect Headache Incidence at 4.5 mg/week 7% Side Effect Indigestion Incidence at 4.5 mg/week 4% Incidence was lower at lower doses
competes with FOXO4 for p53 in senescent cells
Follow-up visit : During the IV/IM therapy plan, a follow-up visit is arranged with the healthcare Prescriber to assess progress on the treatment/ therapy plan, make any necessary adjustments if necessary, and provide ongoing support and guidance
Common LFTs include ALT, AST, ALP, and GGT
In research settings, this peptide is commonly utilized for studying NMDA-receptor-associated neuromodulation, hypothalamic-pituitary-adrenal axis dynamics, and related biochemical mechanisms
